Vocal Abilities Lost to ADNP Syndrome Could be Recovered

by Ramya Rachamanti on  November 16, 2018 at 4:58 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Vocal communication abilities that are lost due to activity-dependent neuroprotective protein syndrome (ADNP syndrome) can be restored by a drug called CP201, reveals a new study.
Vocal Abilities Lost to ADNP Syndrome Could be Recovered
Vocal Abilities Lost to ADNP Syndrome Could be Recovered

Activity-dependent neuroprotective protein syndrome (ADNP syndrome) is a rare genetic condition which causes developmental delays, intellectual disability and autism spectrum disorder symptoms, vocal communication difficulties in many children throughout the world.

CP201 injections have been identified to improve the vocal communication abilities that are poorly developed in ADNP syndrome according to a new Tel Aviv University study.

The research establishes that vocal impediments and disrupted neural connectivity in ADNP-deficient mice were normalized following daily injections and intranasal administrations of CP201.

Research for the groundbreaking study was led by Prof. Illana Gozes, the Lily and Avraham Gildor Chair for the Investigation of Growth Factors and head of the Elton Laboratory for Molecular Neuroendocrinology at TAU's Sackler Faculty of Medicine, in collaboration with Prof. Anne McKinney of McGill University and her research group and Dr. Vlasta Korenková of the BIOCEV Institute of Biotechnology.

TAU doctoral students Gal Hacohen-Kleiman, Shlomo Sragovich, Gidon Karmon, Iris Grigg and Dr. Metsada Pasmanik-Chor conducted the research for the study, which was published in the November print issue of the Journal of Clinical Investigation.

Giving ADNP children a voice

ADNP syndrome is caused by truncating mutations of the ADNP protein, which is essential for brain formation.

"Children with ADNP syndrome suffer from an intellectual disability, delayed language acquisition and speech impediments," says Prof. Gozes, who discovered the ADNP gene nearly 20 years ago. "Many children are never able to speak at all.

"We developed a mouse model of ADNP deficiency that offered a closer look at the ADNP-deficient brain. We discovered that vocal communication deficiencies are in fact connected to synaptic pathology and that we could normalize this by injecting the mouse model with daily NAP treatments or administering intranasal doses to the mouse.

Specific gene regulation substantially improved on most of the parameters that we tested, which is great news for the future of ADNP and autism research."

Prof. Gozes' decades-long ADNP research led to the development of CP201, an important nerve-cell-protecting snippet of ADNP that enhances its activity. It increases nerve cell plasticity that improves memory and cognition through interaction with microtubule end-binding proteins.

"We have seen CP201's positive effects in Alzheimer's and other neurodegenerative diseases," says Prof. Gozes. "We have now found that vocal communication impediments in ADNP-deficient mice were successfully normalized.

The CP201 systemic injections or intranasal daily applications in nonsuckling mice affected global changes in brain plasticity, substantially improving developmental milestones."

The new study was conducted over two years. The researchers used cognitive behavioral tests and gene expression analysis to assess the developmental milestones of 72 ADNP-deficient mice. They also applied ultrasonic vocalization analysis to some 28 ADNP-deficient mice and compared these with the results of 50 "normal" mice.

A promising candidate for clinical trials

Ramot, Tel Aviv University's technology transfer arm, licensed NAP (CP201) to Coronis Neuroscience for development. The U.S. Food and Drug Administration (FDA) has since granted CP201 Orphan Drug status for the treatment of ADNP syndrome in the United States.

According to Prof. Gozes, the current study paves the way for a clinical trial. "NAP (CP201) has demonstrated brain target engagement and great potential for treating social, motor and vocal communication impediments in future intellectual disabilities/autism-oriented clinical trials," she says.

Coronis Neurosciences has just completed a pre-IND (investigational new drug program) meeting with the FDA with positive outcomes and a roadmap to successful IND submission for CP201 in the ADNP syndrome. The IND program is the means by which a pharmaceutical company obtains permission to start human clinical trials.



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive